<DOC>
	<DOCNO>NCT01340976</DOCNO>
	<brief_summary>This study evaluate safety LY2787106 participant cancer anemia . It also evaluate LY2787106 improve anemia . This study two part : Part A dose escalation evaluation . Part B evaluation LY2787106 define dose give without iron supplementation .</brief_summary>
	<brief_title>A Phase 1 Study LY2787106 Cancer Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Have histological cytological evidence nonmyeloid cancer ( solid tumor , lymphomas multiple myeloma ) metastatic and/or incurable Have treat least one systemic ( oral , intravenous , subcutaneous ) anticancer therapy regimen Have hemoglobin less equal 11 g/dL Have hepcidin level great equal 5 ng/mL Have give write informed consent prior studyspecific procedure Have adequate hematologic , hepatic , renal organ function Have Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Available duration study willing follow study procedure If male female reproductive potential : Must agree use medically approve contraception trial 4 month follow last dose study drug If female child bear potential : Have negative serum pregnancy test Have estimate life expectancy great equal 12 week Have receive treatment previous 21 day , recover fully , drug receive regulatory approval indication Have receive erythropoiesisstimulating agent previous 21 day red blood cell transfusion previous 14 day , investigator 's opinion , likely need red blood cell transfusion frequently every 21 day Have receive parenteral iron supplementation within prior 14 day Have document history pure red cell aplasia , thalassemia major sickle cell disease Have history cirrhosis major organ transplantation QTc great 470 msec Have evidence clinically significant hemolysis bleed Have clinically significant systemic infection within 14 day enrollment Have suspect confirmed history hemochromatosis . Have serious preexist medical condition ( leave discretion investigator ) Have symptomatic central nervous system malignancy metastasis ( screen require ) Have acute chronic leukemia Are female pregnant lactating Have history human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C ( screen require ) Have receive external beam radiotherapy 25 % bone marrow Have know clinically significant hypersensitivity biologic agent Have receive live vaccine ( ) within 1 month screen plan participation study Have history congestive heart failure New York Heart Association ( NYHA ) Class great 2 ( NYHA Class 1 2 eligible ) , unstable angina recent myocardial infarction ( within 1 year prior administration study drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Cancer Related Anemia</keyword>
</DOC>